DOCSLIB.ORG

The Bacitracin Biosynthesis Operon of Bacillus Licheniformis ATCC 10716

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Bacitracin Biosynthesis Operon of Bacillus Licheniformis ATCC 10716 Research Paper 927 The bacitracin biosynthesis operon of Bacillus licheniformis ATCC 10716: molecular characterization of three multi-modular peptide synthetases Dirk Konzl, Andrea Klensl, Kurt Schbrgendorfer* and Mohamed A Marahiell Background: The branched cyclic dodecylpeptide antibiotic bacitracin, Addresses: ‘Philipps-Universittit Marburg, produced by special strains of Bacillus, is synthesized nonribosomally by a Fachbereich ChemielBiochemie, Hans-Meerwein- StraOe, 35032 Marburg, Germany. *Biochemie large multienzyme complex composed of the three bacitracin synthetases BAl , GmbH, 6330 Kufstein/Schaftenau, Austria. BA2 and BA3. These enzymes activate and incorporate the constituent amino acids of bacitracin by a thiotemplate mechanism in a pathway driven by a Correspondence: Mohamed A Marahiel protein template. The biochemical features of these enzymes have been studied E-mail: [email protected] intensively but little is known about the molecular organization of their genes. Key words: Bacillus licheniformus, bacitracin, DNA sequence, peptide antibiotics, peptide Results: The entire bacitracin synthetase operon containing the genes synthetases, thiazoline ring bacA-bacC was cloned and sequenced, identifying a modular structure typical of peptide synthetases. The bacA gene product (BAI , 598 kDa) contains five Received: 30 September 1997 Accepted: 28 October 1997 modules, with an internal epimerization domain attached to the fourth; bacB encodes BA2 (297 kDa), and has two modules and a carboxy-terminal Chemistry & Biology December 1997,4:927-937 epimerization domain; bacC encodes BA3, five modules (723 kDa) with http://biomednet.comlelecref/1074552100400927 additional internal epimerization domains attached to the second and fourth. A 0 Current Biology Ltd ISSN 1074-5521 carboxy-terminal putative thioesterase domain was also detected in BA3. A putative cyclization domain was found in BAl that may be involved in thiazoline ring formation. The adenylation/thioester-binding domains of the first two BAl modules were overproduced and the detected amino-acid specificity coincides with the first two amino acids in bacitracin. Disruption of chromosomal bacB resulted in a bacitracin-deficient mutant. Conclusions: The genes encoding the bacitracin synthetases BAl , BA2 and BA3 are organized in an operon, the structure of which reflects the modular architecture expected of peptide synthetases. In addition, a putative thiazoline ring formation domain was identified in the BAl gene. Introduction repeat subunits of peptidoglycan. Recycling of IPP Bacitracins are antibiotic polypeptides produced by involves its dephosphorylation to C,,-isoprenyl phos- certain strains of Bacillus lic/leniformis [1,2] and Bacillus phate (IP) by a phosphatase at the end of each cycle; this suMis [3]. Crudely purified bacitracin contains at least 10 step is blocked by the bacitracin-MZ+-IPP-complex distinct dodecapeptides that differ by one or two amino (where M2+ is a divalent metal ion), resulting in an accu- acids [4]. The most abundant and best characterized of mulation of uridine diphosphate-acetylmuramyl pen- these peptides is bacitracin A (Figure la), a branched tapeptide. This model for bacitracin action is supported cyclic dodecapeptide. It contains an amino-terminal by recently described mechanisms for bacitracin resis- linear pentapeptide moiety with an isoleucine-cysteine tance involving the production of increased IPP [7,8]. thiazoline condensation product and a carboxy-terminal Besides this primary mode of action, bacitracin also heptapeptide ring, in which the free a-carboxy group of seems to affect membrane functions [9], the action of the carboxy-terminal Asn is bound to the E-amino group certain hydrolytic enzymes [lo], and the biosynthesis of of lysine. As well as proteinogenic amino acids, four ubiquinone precursors [ 111. amino acids in the D-configuration (Glu4,Orn7, Phe9 and Aspll) and the nonproteinogenic residue ornithine (Orn) Like many other peptide antibiotics from Bacdus [12], are incorporated into bacitracin A. Bacitracin A is most bacitracin is produced nonribosomally by a large multi- active against Gram-positive bacteria and acts by inhibit- enzyme complex [13-151 utilizing a thiotemplate mecha- ing bacterial cell-wall biosynthesis: bacitracin A forms a nism [16-201. In this mechanism, large multifunctional tight ternary complex with C,,-isoprenyl pyrophosphate enzymes, designated peptide synthetases, activate their (IPP) and a divalent metal cation [5,6]. IPP serves as a substrate amino acids as aminoacyl adenylates using ATP membrane-associated carrier during the synthesis of the hydrolysis. These unstable intermediates are subsequently 928 Chemistry & Biology 1997, Vol 4 No 12 Figure 1 (a) BAl BA2 (b) I Ile CYS Thloesterase HP\H-CH+~- Leu - D-Leu - Ile - Lys - D-Om - Ile - D-Phe Asn -D-Asp -His Thiazollne Thioester formatlon (T) w 0 2 4 6 6 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 kb 1) I I I II I 11 11 11 11 I ” 1 ’ 1 ’ 1 ’ 11 81 11 1 11 11 11 11 11 11 I I bacA bacB bacC PCROS (d) 1 h.A14.3 (e) m POE-BacAi i@i-&$// pBAC-BA POE-BacAZ Chemistry & Biolog!I (a) Primary structure of bacitracin A. Brackets embrace the residues domain organization of the peptide synthetases is illustrated within the incorporated by the three bacitracin synthetases BAl , BA2 and BA3. genes. (d) PCR fragment 05 used for the screening of the h-EMBL3 The thiazoline ring, a product of isoleucine and cysteine cyclization, is genomic library and h clones isolated in this work. Probes A and B used highlighted in yellow. (b) The color code of the patterns used for for chromosomal walking are marked in light blue. (e) Gene fragments, different domains in the remainder of the figure. (c) Physical corresponding to AT domains, were overexpressed and biochemically organization of the bat operon. Three genes, bacA, 6acB and bacC analyzed. Plasmid pBAC-BA was used for the construction of a bacB coding for the bacitracin synthetases BAl -BA3 were identified. The gene disruption mutant. Abreviations: Orn, ornithine; E, EcoRl; S, WT. transferred to a covalently enzyme-bound 4’-phospho- belongs to the large family of adenylate-forming enzymes pantetheinyl (4’-PP)-cofactor as thioesters. The peptide that includes firefly luciferase [28] and the acetyl-CoA syn- product is generated by the stepwise incorporation of the thetases [ZZ]. The adjacent thioester-binding (T) domain thioesterified amino acids in a series of amino- to carboxy- (80 amino acids) shares high homology with the acyl carrier terminal-directed transpeptidations. Thorough sequence protein (ACP) that is involved in fatty acid and polyketide analysis of several genes encoding peptide synthetases has synthesis. It contains the highly conserved sequence motif unveiled a modular organization principle for this class of LGGxJ’I (using single-letter amino-acid code, with x as enzymes [l&21-231. The detected modules (around 1000 any amino acid) with an invariant serine residue (itali- amino acids each) are responsible for the activation and cized), which is the 4’-PP-attachment site [29-311. In con- incorporation of a single amino acid and thus are arranged trast to the original model of the thiotemplate mechanism, in a colinear fashion with the product peptide [B-26]. If a which suggested that a single 4’-PP-cofactor would act as a biosynthetic complex consists of several peptide syn- ‘swinging arm’ to transfer the growing peptide chain from thetases, the colinearity of the modules is conserved one module to the next, the presence of such a cofactor at within each single enzyme [17,18]. Each module can be each module of a multimodular PPS has recently been subdivided into several specific domains [20,22,27]. The shown [32]; this finding established the ‘multiple carrier adenylation (A) domain (550 amino acids) is the elemen- model’ for nonribosomal peptide synthesis. The T domain tary domain of each module and catalyzes the specific acti- is followed by a recently reported condensation (C) vation of a given substrate amino acid. This module domain (3.50 amino acids), which is thought to catalyze Research Paper Bacitracin biosynthesis operon Konz et a/. 929 peptide bond formation [33]. Within peptide synthetases stage [37], so an unusual organization of the first two BAl with a single polypeptide chain, the C domain is always modules is to be expected. found between two A domains. If the peptide biosynthesis complex is composed of several peptide synthetases, the In this study we report the cloning and sequencing of the subunit that activates the first amino acid of the peptide entire bat operon from B. l&enzj&nis. Three genes, bacA, lacks a C domain. The C domain is found instead at the bacB and bad‘, coding for the three biochemically identified amino-terminal end of subunits that catalyze activation bacitracin synthetases were sequenced. The genes reflect and transfer of the distal amino acids of the peptide. In the typical structure of a peptide synthetase, with five modules that catalyze the incorporation of N-methylated modules in bacA, two in bacB and five in bad’. The chromo- amino acids, an additional N-methylase domain (350 amino somal arrangement of the genes is in the same order as their acids) is inserted between the A and T domains [24,25]. If biochemical action. Complete sequence analysis of bacA the module introduces D-amino acids, the T domain is fol- and bacC revealed that they contain modules with internal lowed by an epimerization (E) domain (400 amino acids) E domains, the first example of these domains in prokary- [27,34]. In many bacterial systems the module that cat- otic peptide synthetases. In addition, a strongly modified C alyzes the incorporation of the carboxy-terminal amino domain was identified between the first two A domains of acid of the product peptide contains an additional putative bacA; this region shares highest homologies with proteins thioesterase (Te) domain; Te domains are thought to play involved in the nonribosomal synthesis of thiazoline-con- a role in peptide chain release or cyclization [ZO].
Load more

Recommended publications
  • Neomycin and Polymyxin B Sulfates Solution for Irrigation, USP Rx Only
    NEOMYCIN AND POLYMYXIN B SULFATES- neomycin and polymyxin b sulfates solution X-GEN Pharmaceuticals, Inc. ---------- Neomycin and Polymyxin B Sulfates Solution for Irrigation, USP Rx Only NOT FOR INJECTION DESCRIPTION Neomycin and Polymyxin B Sulfates Solution for Irrigation is a concentrated sterile antibiotic solution to be diluted for urinary bladder irrigation. Each mL contains neomycin sulfate equivalent to 40 mg neomycin base, 200,000 units polymyxin B sulfate, and Water for Injection, inactive ingredient: sulfuric acid. The 20-mL multiple dose vial contains, in addition to the above, 1 mg methylparaben (0.1%) added as a preservative. Neomycin sulfate, an antibiotic of the aminoglycoside group, is the sulfate salt of neomycin B and C produced by Streptomyces fradiae It has a potency equivalent to not less than 600 mcg of neomycin per mg. The structural formulae are: Polymyxin B sulfate, a polypeptide antibiotic, is the sulfate salt of polymyxin B1 and B2 produced by the growth of Bacillus polymyxa. It has a potency of not less than 6,000 polymyxin B units per mg. The structural formulae are: CLINICAL PHARMACOLOGY After prophylactic irrigation of the intact urinary bladder, neomycin and polymyxin B are absorbed in clinically insignificant quantities. A neomycin serum level of 0.1 mcg/mL was observed in three of 33 patients receiving the rinse solution. This level is well below that which has been associated with neomycin-induced toxicity. When used topically, polymyxin B sulfate and neomycin are rarely irritating. Microbiology: The prepared Neomycin and Polymyxin B Sulfates Solution for Irrigation is bactericidal. The aminoglycosides act by inhibiting normal protein synthesis in susceptible microorganisms.
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Conjunctivitis Or Worse?
    Red Eye in Dogs and CatS: Conjunctivitis or Worse? Tracy Revoir, DVM Senior Manager of Veterinary Support, Dechra Veterinary Products It should come as no surprise that conjunctivitis is Common Causes of Conjunctivitis the most common ophthalmic disorder in dogs and cats. But because the clinical signs of conjunctivitis If you do confirm conjunctivitis, the next step is can mimic those of more serious ophthalmic identifying the cause. If both eyes are affected and diseases (glaucoma and uveitis), it’s important to abnormal clinical signs are apparent in other body confirm your diagnosis. systems, think underlying systemic disease. If only one eye is affected, rule out infection, tear film What are important clues to the severity of the deficiencies, an irritant, anatomical abnormality, condition? With conjunctivitis, the inflammation or deeper ocular disease. should be limited to the conjunctiva. Hyperemic conjunctival vessels are superficial, branching, In dogs, conjunctivitis can result from anatomical and bright red. They are movable over the deeper disorders, irritants, infection (usually bacterial), or episcleral vessels and can be blanched with topical atopy. Most bacterial infections are secondary dilute phenylephrine. With glaucoma and uveitis, the conditions, most often to allergies. In cats, herpes- episcleral vessels are engorged; they are dark red, virus and Chlamydophila felis are the most common deep, straight, and immobile and do not blanch with causes of conjunctivitis. Atopy can also be topical dilute phenylephrine. With conjunctivitis, an issue in cats. the Schirmer tear test and intraocular pressures are normal. And the cornea should be clear and no aqueous flare should be present. The pupil and Addressing the Problem pupillary responses are normal and intraocular structures should be visible.
    [Show full text]
  • Topical Antibiotics for Impetigo: a Review of the Clinical Effectiveness and Guidelines
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: February 21, 2017 Report Length: 23 Pages Authors: Rob Edge, Charlene Argáez Cite As: Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines. Ottawa: CADTH; 2017 Feb. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Farrukh Javaid Malik
    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
    [Show full text]
  • Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP)
    NDA 50-417/S-011 Page 3 NEOSPORIN® Ophthalmic Ointment Sterile (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment, USP) Description: NEOSPORIN Ophthalmic Ointment (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment) is a sterile antimicrobial ointment for ophthalmic use. Each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, bacitracin zinc equivalent to 400 bacitracin units, and white petrolatum, q.s. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 µg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: [Structure] Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: [Structure] Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units per mg. The structural formula is: [Structure] CLINICAL PHARMACOLOGY: A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin. Neomycin is bactericidal for many gram-positive and gram-negative organisms.
    [Show full text]
  • Subpart J—Certain Other Dosage Forms [Reserved] PART
    Pt. 448 21 CFR Ch. I (4±1±96 Edition) (ii) Samples required: Subpart HÐRectal Dosage Forms (a) The oxytetracycline hydro- [Reserved] chloride used in making the batch: 10 packages, each containing approxi- mately 300 milligrams. Subpart IÐ[Reserved] (b) The polymyxin B sulfate used in making the batch: 10 packages, each Subpart JÐCertain Other Dosage containing approximately 300 milli- Forms [Reserved] grams. (c) The batch: A minimum of 30 tab- PART 448ÐPEPTIDE ANTIBIOTIC lets. DRUGS (b) Tests and methods of assayÐ(1) Po- tencyÐ(i) Oxytetracycline content. Pro- Subpart AÐBulk Drugs ceed as directed in § 436.106 of this chap- ter, preparing the sample for assay as Sec. 448.10 Bacitracin. follows: Place a representative number 448.10a Sterile bacitracin. of tablets into a high-speed glass blend- 448.13 Bacitracin zinc. er jar containing sufficient 0.1N hydro- 448.13a Sterile bacitracin zinc. chloric acid to obtain a stock solution 448.15a Sterile capreomycin sulfate. of convenient concentration containing 448.20a Sterile colistimethate sodium. not less than 150 micrograms of oxytet- 448.21 Colistin sulfate. racycline per milliliter (estimated). 448.23 Cyclosporine. Blend for 3 to 5 minutes. Remove an al- 448.25 Gramicidin. iquot of the stock solution and further 448.30 Polymyxin B sulfate. dilute with sterile distilled water to 448.30a Sterile polymyxin B sulfate. the reference concentration of 0.24 448.75 Tyrothricin. microgram of oxytetracycline per mil- liliter (estimated). Subpart BÐOral Dosage Forms (ii) Polymyxin B content. Proceed as 448.121 Colistin sulfate for oral suspension. directed in § 436.105 of this chapter, pre- 448.123 Cyclosporine oral dosage forms.
    [Show full text]
  • (ESVAC) Web-Based Sales and Animal Population
    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.
    [Show full text]
  • New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics
    pharmaceuticals Review New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics Nicola Principi 1, Alberto Argentiero 2, Cosimo Neglia 2, Andrea Gramegna 3,4 and Susanna Esposito 2,* 1 Università degli Studi di Milano, 20122 Milan, Italy; [email protected] 2 Pediatric Clinic, Pietro Barilla Children’s Hospital, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy; [email protected] (A.A.); [email protected] (C.N.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, 20122 Milan, Italy; [email protected] 4 Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-052-190-3524 Received: 29 September 2020; Accepted: 19 October 2020; Published: 23 October 2020 Abstract: Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to Gram-positive bacteria, especially Staphylococcus aureus and Streptococcus pyogenes. aSSTI incidence increased considerably in the early years of this century due to the emergence and diffusion of community-acquired methicillin-resistant S. aureus (CA-MRSA). Despite the availability of antibiotics effective against CA-MRSA, problems of resistance to these drugs and risks of significant adverse events have emerged. In this paper, the present knowledge on the potential role new antibiotics for the treatment of pediatric aSSTIs is discussed. The most recent molecules that have been licensed for the treatment of aSSTIs include ozenoxacin (OZ), ceftaroline fosamil (CF), dalbavancin (DA), oritavancin (OR), tedizolid (TD), delafloxacin (DL), and omadacycline (OM).
    [Show full text]
  • WHO Model List (Revised April 2003) Explanatory Notes
    13th edition (April 2003) Essential Medicines WHO Model List (revised April 2003) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings. When the strength of a drug is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as". The square box symbol (? ) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]